ANTIDIABETICS AND APREPITANT
Aprepitant reduces the AUC of tolbutamide by about 25%. Fosaprepitant is a prodrug of aprepitant and would be expected to interact similarly.
As the clinical relevance of this reduction has not been assessed the manufacturer advises caution, but changes of this magnitude are rarely clinically significant.
As the clinical relevance of this reduction has not been assessed the manufacturer advises caution, but changes of this magnitude are rarely clinically significant.